[Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol

CONCLUSION: Our study shows that CZP is effective in real clinical practice in patients with moderate-severe plaque PsO, with an improvement in absolute PASI and DLQI, as well as other scales, both for the total population and in the subgroups analysed. Nearly 91% of patients reached the therapeutic target fixed in the RSA. Implementing this type of agreement can provide a direct or indirect benefit for all the agents involved in the process, providing valuable information for decision-making.PMID:38148255 | DOI:10.1016/j.farma.2023.11.004

Source: Farmacia Hospitalaria - December 26, 2023 Category: Drugs & Pharmacology Authors: Andr és Navarro Ruiz Fernando Toledo Alberola Susana Aceituno Grupo ARCODERM Source Type: research